Ebola vaccine based on 2014 virus strain is safe, trial shows
Source: A Dowsett, Health Protection Agency / Science Photo Library
Until now, all Ebola virus vaccines have been based on a strain from the Zaire outbreak in 1976, which shares 97.6% similarity with the 2014 west African strain. Taking a new approach, Chinese researchers have developed a recombinant adenovirus type-5 vector-based Ebola vaccine that expresses the envelope glycoprotein from the 2014 epidemic strain.
Two doses of the novel vaccine were evaluated in a randomised, double-blind, phase I study involving 120 healthy adults. The higher dose was safe and “robustly immunogenic” with a 100% response rate and no serious adverse events, the researchers report in The Lancet (online, 24 March 2015).
The vaccine will now be evaluated in a phase II trial in outbreak regions.
Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2015.20068226
Recommended from Pharmaceutical Press